• Home
  • »
  • Biotechnology
  • »
  • Circulating Tumor Cells Market Size, Industry Report, 2030
GVR Report cover Circulating Tumor Cells Market Size, Share & Trends Report

Circulating Tumor Cells Market Size, Share & Trends Analysis Report By Application (Clinical, Research), By Specimen (Bone Marrow, Blood), By Product, By Technology, By End Use, By Region, And Segment Forecasts, 2025 - 2030

  • Report ID: 978-1-68038-287-7
  • Number of Report Pages: 120
  • Format: PDF, Horizon Databook
  • Historical Range: 2018 - 2024
  • Forecast Period: 2025 - 2030 
  • Industry: Healthcare

Circulating Tumor Cells Market Size & Trends

The global circulating tumor cells market size was estimated at USD 12.62 billion in 2024 and is projected to grow at a CAGR of 12.2% from 2025 to 2030. Owing to their noninvasiveness and advantages, circulating tumor cells (CTCs) are considered a promising tool in cancer diagnosis. In addition, technological advancements in chip technology are another key factor driving market growth.

Circulating Tumor Cells Market Size, By Technology, 2020 - 2030 (USD Billion)

Increasing cancer incidence across the globe is one of the major drivers for market growth. In 2023, the Pan American Health Organization reported around 20 million newly diagnosed cancer cases and 10 million cancer-related deaths. Projections indicate a probable 60% surge in the cancer burden over the next two decades, posing additional challenges to healthcare systems, individuals, and communities. It is anticipated that the global incidence of new cancer cases is expected to rise to approximately 30 million by the year 2040. In addition, circulating tumor cells in breast cancer diagnosis are released in the bloodstream by cancerous tumors.

As per Breast Cancer Statistics and Resources, it is anticipated that in 2023, around 297,790 women receive a diagnosis of breast cancer in the U.S., solidifying its status as the most prevalent cancer among American women. The rising burden of cancer also attracts increased investment in research and development for new cancer therapies & technologies. CTCs that actively participate in clinical trials and adopt innovative treatment options can attract patients seeking cutting-edge care, further boosting their market position.

Over the last several decades, extensive translational and clinical cancer research programs have been conducted in the field of CTCs. The ongoing research on circulating tumor cell technology by several government bodies, such as the American Association of Cancer Research and the American Society of Clinical Oncology, to utilize it as a surrogate marker for determining cancer progression is expected to aid market growth.

Furthermore, the rising adoption of biomarker tests enables minimally invasive screening of tumors before opting for complex surgical procedures, such as radiotherapy, chemotherapy, and surgical removal of tumors. Therefore, due to their simpler nature, the high demand for noninvasive procedures is anticipated to considerably impact the CTC market over the forecast period.

Advancements In Chip Technology

The ongoing advancements in chip technology have positively impacted market growth. Cluster chip technology plays a role in capturing the exceptionally rare group of cells, such as CTCs. Isolation of CTCs is a cumbersome process and requires high accuracy. Chip technology helps perform precise CTC isolation but also helps overcome the challenges associated with isolation devices developed by key companies. The challenges include lower sensitivity, the inability to capture CTCs of all sizes & types, high manufacturing costs, and difficulty retrieving captured CTCs from the devices for further laboratory analysis. Moreover, the white blood cells that contaminate trapped CTCs, which are similar in size, can be mistakenly regarded as CTCs, a limitation associated with these devices.

These challenges can be overcome by developing a chip composed of carbon nanotubes. Researchers from the Worcester Polytechnic Institute, Massachusetts, developed a chip made of carbon nanotubes, which overcomes these challenges and boosts the capturing of CTCs, as reported in a research study published in April 2019. White blood cells do not adhere to the nanotubes, leaving only CTCs for enumeration. Another advantage of this chip is that it captures individual CTCs exhibiting multiple phenotypes from early- and late-stage cancer patients. Moreover, the CTCs captured by nanotubes remain viable and can even be cultured. As these chips are transparent, it makes it easier for researchers to stain and study captured CTCs without removing them.

Market Concentration & Characteristics

The market for CTCs has seen significant innovation in recent years. Some of the recent innovations include the development of microfluidic chips for CTC capture, the use of imaging techniques for circulating tumor cell detection, and the implementation of machine learning algorithms for CTC analysis. These advances can revolutionize cancer care by providing more accurate and reliable information about a patient's disease status.

The circulating tumor cells industry is also characterized by the leading players' high level of merger and acquisition (M&A) activity. M&A drives companies to focus on specific applications of CTC technology, such as early cancer detection, treatment monitoring, or personalized medicine. This could lead to more targeted and effective circulating tumor cell tests and therapies. For instance, in May 2023, Menarini Silicon Biosystems partnered with Alivio Health to provide access to its CELLSEARCH liquid biopsy tests for Alivio Health's clients and members. CELLSEARCH tests provide noninvasive analysis of CTCs to help in clinical decision-making, potentially leading to earlier diagnosis and more effective treatment strategies.

Circulating Tumor Cells Industry Dynamics

Regulations can have a significant impact on the CTC market. Regulatory bodies such as the FDA play a crucial role in determining the safety and efficacy of CTC products. Stringent regulations can lead to delays in approving new CTC products, which can slow innovation and limit the options available to patients and healthcare providers.

As the circulating tumor cells industry evolves, companies are expanding their product offerings through new technologies, strategic collaborations, and integration with multi-omics approaches. For instance, in December 2021, Epic Sciences launched DefineMBC, a blood-based test designed to improve care for patients with metastatic breast cancer.

As the CTC market grows, regional expansion plays a crucial role in increasing market penetration, regulatory approvals, and adoption rates. Increasing adoption in developing countries due to rising cancer cases & government initiatives is a major driver for regional expansion. For instance, China: CFDA (NMPA) has approved CellSearch for CTC detection, boosting hospital adoption.

Technology Insights

The CTC detection and enrichment methods segment accounted for the largest revenue share of 40.92% in 2024. The availability of different methods to enrich circulating tumor cells in cancer detection is expected to significantly impact segment growth over the forecast period. Moreover, positive or negative enrichment of CTCs based on biological properties is expected to hold significant potential for market growth. An effective enrichment process helps enhance sensitivity, selectivity, and yield, thereby ensuring successful clinical translation of this field. Different techniques for CTC detection include magnetic beads-based centrifugal force, enrichment, filtration, and other physical properties such as density, deformity, size, & electric charges.

CTC analysis is expected to register the fastest CAGR during the forecast period. Understanding subclonal intratumor heterogeneity using CTC detection can help clinicians determine the underlying reasons for unresponsive patients subjected to targeted therapy, eventually leading to enhanced cancer therapies. Hence, CTC analysis is a minimally invasive method in repetitive analysis and validated technology for tumor study & clinical decision-making.

Moreover, technological advancements such as immunofluorescence, Next-Generation Sequencing (NGS), fluorescence in situ hybridization (FISH), and quantitative PCR (qPCR) are anticipated to improve CTC analyses. Hence, due to the fundamental principle of amplification in qPCR, the detection of CTCs in a large blood sample becomes efficient and accurate.

Application Insights

Clinical applications dominated the market and captured the largest revenue share in 2024. In a liquid biopsy, the analysis of CTCs in a cancer patient’s bloodstream has received significant attention for their potential clinical utility. The number of CTCs in a patient’s blood can differ based on cancer type, stage, and treatment. The number of CTCs found in the patient’s bloodstream indicates the state of the disease. Patients in the later stages of cancer show a higher number of CTCs than patients in the early stages of cancer.

The research segment is expected to register a significant CAGR during the forecast period. CTCs are regarded as a substrate of cancer metastasis. Currently, the enumeration of CTCs represents an effective predictive and prognostic biomarker capable of monitoring the efficacy of adjuvant therapies, identifying early development of metastases, and evaluating therapeutic responses better than conventional imaging methods. In addition, CTC enumeration remains largely a research tool.

Recently, the focus has shifted toward CTC characterization and isolation, which can provide significant opportunities in predictive testing research. For instance, in April 2021, Bio-Techne Corporation acquired Asuragen, Inc. for USD 215 million. Asuragen’s expertise in productizing lab-developed tests and commercializing innovative molecular products allowed Bio-Techne to offer advanced solutions to researchers and clinicians.

Product Insights

The kits & reagents segment dominated the market and accounted for the largest revenue share of 45.34% in 2024. This can be attributed to frequent purchases and high usage rates. For instance, CellSearch Circulating Tumour Cell Kit, authorized by the U.S. FDA, is one the most popular products produced in the U.S. In addition, the availability of a robust product portfolio coupled with advancements in microfluidics technology is expected to propel the market growth.

The devices or systems segment is expected to grow at the fastest CAGR during the forecast period. The introduction of fabricated glass microchips to overcome the challenges and to increase technical completeness for mass production is expected to propel the segment growth. The development of automated instruments that eliminate the use of additional blood collection tubes reduces the cost of blood collection tubes.

The cost reduction is also observed as transportation is free of the additional laboratory consumables and transfer tubes when the reagent-equipped tubes are used. On the other hand, kits and reagents have also contributed significantly to the segment’s revenue.

Specimen Insights

The blood specimen segment dominated the market and accounted for the largest revenue share of 48.13% in 2024. A large concentration of these cells in blood samples compared with other biospecimens is responsible for the largest penetration of this specimen type. Approaches for tumor cell identification in blood samples are considered important in current cancer research, as they aid in predicting prognosis and determining the response to systemic chemotherapy. However, using whole blood as a specimen poses a challenge when combined with microfluidic technology.

The bone marrow segment is expected to register a significant CAGR during the forecast period. Bone marrow samples, when analyzed for CTCs, play a vital role in cancer research and clinical trials. Researchers use these samples to study the biology of circulating tumor cells, understand the mechanisms of metastasis, and develop novel therapeutic approaches. These factors are expected to support segment growth in the forecast years.

End Use Insights

Hospital and clinics dominated the market and accounted for the largest revenue share of 37.64% in 2024. This is due to their advanced technology and expertise in detecting and analyzing CTCs. They have access to advanced equipment and trained professionals who can perform accurate and reliable tests. The large share of the segment is due to direct patient care, treatment planning, and integration with oncology departments. Moreover, the increasing adoption of liquid biopsy for cancer monitoring is also attributed to segment growth.

Circulating Tumor Cells Market Share, By End Use, 2024 (%)

Research and academic institutes.is expected to register the highest CAGR during the forecast period. This can be attributed to the increasing focus on research and development activities for cancer diagnosis and treatment. These institutes invest heavily in advanced technologies and equipment to enhance CTC detection and analysis accuracy and efficiency.

Competitive Analysis

Competitive Analysis

The table evaluates key circulating tumor cell market players based on parameters such as product portfolio, strategic initiatives, and geographic presence. QIAGEN, Bio-Rad Laboratories, and Miltenyi Biotec exhibit high scores across all parameters, indicating a strong product portfolio, strategic initiatives, and global presence. These companies are well-positioned in the market due to their broad offerings and international reach. Ikonisys Inc. and Creative Biolarray show medium rankings in strategic initiatives while maintaining high scores in other areas. This suggests that while they have strong market penetration, they may need to enhance their strategic initiatives to remain competitive. Bio-Techne Corporation and Epic Sciences have room for growth in expanding collaborations, partnerships, and innovation strategies.

Regional Insights

North America captured the largest market share of 40.91% in 2024. The key players operating in the region are undertaking various strategies to enhance their market hold, a key factor responsible for the high share of the U.S. The U.S. is anticipated to significantly contribute to the regional market's growth due to factors including the rising incidence of cancer, product approvals, and increased R&D efforts. For instance, the American Cancer Society projects that there are approximately 127,070 lung cancer fatalities nationwide and about 238,340 new instances of lung cancer diagnosis in 2023. Furthermore, a population with high cancer susceptibility, increased market penetration rates, and technologically advanced cancer care infrastructure support the region’s growth.

Circulating Tumor Cells Market Trends, by Region, 2025 - 2030

U.S. Circulating Tumor Cells Market Trends

The circulating tumor cells industry in the U.S. benefits from extensive clinical research activities and the strong presence of biotechnology firms developing innovative CTC isolation technologies. The country's favorable regulatory environment for liquid biopsy products and growing investment in precision oncology are accelerating the adoption of CTC-based tests for monitoring treatment response and detecting minimal residual disease.

Europe Circulating Tumor Cells Market Trends

The CTC market in Europe is expanding due to the increasing adoption of liquid biopsy solutions for cancer management. Research institutions and healthcare providers across the region are actively exploring CTC technologies for early detection, prognosis, and therapy monitoring. Strong regulatory support and funding for oncology research are further accelerating market growth.

The UK circulating tumor market is experiencing significant growth due to growing investments in precision medicine initiatives. Collaborative research projects drive the development of CTC-based diagnostic tools. The National Health Service (NHS) is progressively adopting liquid biopsy methods, supporting the demand for CTC technologies in clinical practice.

The circulating tumor market in Germany is growing due to their well-established healthcare infrastructure, coupled with strong academic research in oncology, which is propelling the adoption of CTC analysis. The country's focus on developing advanced cancer diagnostic tools and increased funding for personalized medicine projects are major growth drivers.

Asia Pacific Circulating Tumor Cells Market Trends

The circulating tumor cells market in Asia Pacific is witnessing growing demand for CTC technologies due to an increasing cancer burden, rising healthcare expenditure, and expanding research initiatives. Countries like China and Japan invest heavily in developing liquid biopsy tools, boosting market growth. Government support for cancer diagnostics and growing awareness about non-invasive testing further propel adoption.

China circulating tumor cells industry growth is driven by increasing investments in biotechnology research and collaborations between domestic and international firms. The country's focus on precision medicine and rising cancer incidence have created significant demand for CTC-based diagnostic tools, particularly for lung and gastric cancers.

The circulating tumor cells market in Japan is growing due to advancements in molecular diagnostics and strong research capabilities. The country's emphasis on early cancer detection and personalized medicine has increased the integration of CTC analysis in clinical practice, particularly for breast and prostate cancer.

MEA Circulating Tumor Cells Market Trends

The circulating tumor cells (CTC) market in the Middle East & Africa is gaining momentum due to increasing investments in healthcare infrastructure and growing awareness of advanced cancer diagnostics. The region’s rising cancer burden and efforts to improve early detection and personalized medicine moderately drive demand for innovative technologies like CTC analysis. Partnerships between healthcare institutions and global biotech firms are further accelerating the adoption of liquid biopsy solutions.

Saudi Arabia CTC market is supported by the government's healthcare reforms under Vision 2030, which emphasize advanced diagnostic technologies and improved cancer care. Rising investments in precision medicine and initiatives to enhance oncology research capabilities are fostering demand for CTC-based testing for early detection and monitoring of metastatic cancers.

The circulating tumor cells market in Kuwait is growing significantly due to the growing prevalence of cancer and increasing investments in diagnostic innovations. The country's healthcare sector is expanding its focus on precision oncology, with medical institutions exploring noninvasive methods like CTC analysis to improve cancer diagnosis, prognosis assessment, and treatment monitoring.

Key Circulating Tumor Cells Company Insights

Key players mostly adopted partnerships, acquisitions, and expansion strategies. Companies such as Bio-Techne have acquired smaller companies with advanced technologies to expand their market reach globally.

Key Circulating Tumor Cells Companies:

The following are the leading companies in the circulating tumor cells market. These companies collectively hold the largest market share and dictate industry trends.

  • QIAGEN
  • Bio-Techne Corporation
  • Precision Medicine Group, LLC.
  • Bio-Rad Laboratories, Inc.
  • Natera, Inc.
  • Illumina, Inc.
  • Cell Microsystems
  • Greiner Bio One International GmbH
  • Ikonisys Inc.
  • Miltenyi Biotec
  • Creative Bioarray
  • BioFluidica
  • Abnova Corporation
  • Biolidics Limited
  • Creatv MicroTech, Inc.
  • LungLife AI, Inc.
  • Epic Sciences
  • Rarecells Diagnostics
  • ScreenCell
  • Menarini Silicon Biosystems
  • APPLIED DNA SCIENCES, INC.
  • Sysmex Corporation
  • STEMCELL Technologies, Inc.

View a comprehensive list of companies in the Circulating Tumor Cells Market

Recent Developments

  • In March 2024, Bio-Rad Laboratories, Inc. launched validated antibodies for rare cell and circulating tumor cell (CTC) enumeration, enhancing tools available for CTC research and diagnostics.

  • In August 2023, Cell Microsystems acquired Fluxion Biosciences, Inc. This acquisition enabled precise measurement of electrical currents across cell membranes, providing insights into ion channel activity and cell signaling.

  • In June 2023, Bio-Techne announced the acquisition of LunaPhore, a Swiss company developing advanced tissue imaging and analysis technologies. By integrating LunaPhore's expertise into its existing portfolio, Bio-Techne aimed to create a comprehensive, end-to-end workflow for researchers studying tissues. The acquisition is expected to close in the first quarter of 2024.

  • In March 2023, Miltenyi Biotec acquired Lino Biotech AG. This acquisition of Lino Biotech's innovative biosensor technology was expected to help develop new & improved assays and quality control processes in the field.

Circulating Tumor Cells Market Report Scope

Report Attribute

Details

Market size value in 2025

USD 14.04 billion

Revenue forecast in 2030

USD 24.96 billion

Growth rate

CAGR of 12.2% from 2025 to 2030

Actual data

2018 - 2024

Forecast period

2025 - 2030

Quantitative units

Revenue in USD billion and CAGR from 2025 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Technology, application, product, specimen, end use, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; Mexico; Germany; UK; France; Italy; Spain; Sweden; Denmark; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Argentina; Saudi Arabia; Kuwait; UAE; South Africa

Key companies profiled

QIAGEN; Bio-Techne Corporation; Precision Medicine Group, LLC.; Bio-Rad Laboratories, Inc.; Natera, Inc.; Illumina, Inc.; Cell Microsystems; Greiner Bio One International GmbH; Ikonisys Inc.; Miltenyi Biotec; Creative Bioarray; BioFluidica; Abnova Corporation; Biolidics Limited; Creatv MicroTech, Inc.; LungLife AI, Inc.; Epic Sciences; Rarecells Diagnostics; ScreenCell; Menarini Silicon Biosystems; APPLIED DNA SCIENCES, INC.; Sysmex Corporation; STEMCELL Technologies, Inc.

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Global Circulating Tumor Cells Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global circulating tumor cells market report based on technology, application, product, specimen, end use, and region:

  • Technology Outlook (Revenue, USD Billion, 2018 - 2030)

    • Circulating Tumor Cells CTC Detection & Enrichment Methods

      • Immunocapture (Label-based)

        • Positive Selection

        • Negative Selection

      • Size-based Separation (Label-free)

        • Membrane-based

        • Microfluidic-based

      • Density-based Separation (Label-free)

      • Combined Methods

    • CTC Direct Detection Methods

    • CTC Analysis

  • Application Outlook (Revenue, USD Billion, 2018 - 2030)

    • Clinical

      • Risk Assessment

      • Screening and Monitoring

    • Research

      • Cancer Stem Cell & Tumorogenesis Research

      • Drug/Therapy Development

  • Product Outlook (Revenue, USD Billion, 2018 - 2030)

    • Kits & Reagents

    • Blood Collection Tubes

    • Devices or Systems

  • Specimen Outlook (Revenue, USD Billion, 2018 - 2030)

    • Blood

    • Bone Marrow

    • Other Body Fluids

  • End Use Outlook (Revenue, USD Billion, 2018 - 2030)

    • Research and Academic Institutes

    • Hospital and Clinics

    • Diagnostic Centers

  • Regional Outlook (Revenue, USD Billion, 2018 - 2030)

    • North America

      • U.S.

      • Canada

      • Mexico

    • Europe

      • Germany

      • UK

      • France

      • Italy

      • Spain

      • Sweden

      • Denmark

      • Norway

    • Asia Pacific

      • China

      • Japan

      • India

      • South Korea

      • Australia

      • Thailand

    • Latin America

      • Brazil

      • Argentina

    • Middle East and Africa (MEA)

      • South Africa

      • UAE

      • Saudi Arabia

      • Kuwait

Frequently Asked Questions About This Report

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation & Scope
                    1.2. Segment Definitions
                        1.2.1. Technology
                        1.2.2. Application
                        1.2.3. Product
                        1.2.4. Specimen
                        1.2.5. End use
                    1.3. Research Methodology
                    1.4. Information Procurement
                    1.5. Information or Data Analysis
                        1.5.1. Data analysis models
                    1.6. Market Formulation & Validation
                    1.7. List of Secondary Sources
                    1.8. List of Primary Sources
                    1.9. Objectives
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Outlook
                    2.3. Competitive Insights
Chapter 3. Circulating Tumor Cells Market Variables, Trends & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent market outlook
                        3.1.2. Related/ancillary market outlook
                    3.2. Market Dynamics
                        3.2.1. Market driver analysis
                            3.2.1.1. Advancements in chip technology
                            3.2.1.2. Expanding applications of CTCs
                            3.2.1.3. Growing demand for early and rapid cancer diagnosis
                            3.2.1.4. Growing incidence of cancer
                        3.2.2. Market restraint analysis
                            3.2.2.1. Consistency-related challenges in CTC detection and enrichment
                            3.2.2.2. Higher preference for Point-of-Care (POC) testing and nonavailability of POC adaptable CTC tests
                            3.2.2.3. Lower applicability of CTCs in rare cancers
                    3.3. Circulating Tumor Cells Market Analysis Tools
                        3.3.1. Industry Analysis - Porter’s
                        3.3.2. PESTEL Analysis
                        3.3.3. COVID-19 Impact Analysis
Chapter 4. Circulating Tumor Cells Market: Technology Estimates & Trend Analysis
                    4.1. Technology Segment Dashboard
                    4.2. Global Circulating Tumor Cells Market Technology Movement Analysis
                    4.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
                    4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
                        4.4.1. CTC Detection & Enrichment Methods
                            4.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
                            4.4.1.2. Immunocapture (Label-based)
                                4.4.1.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
                                4.4.1.2.2. Positive Selection
                                    4.4.1.2.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
                                4.4.1.2.3. Negative Selection
                                    4.4.1.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
                            4.4.1.3. Size-based Separation (Label-free)
                                4.4.1.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
                                4.4.1.3.2. Membrane-based
                                    4.4.1.3.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
                                4.4.1.3.3. Microfluidic-based
                                    4.4.1.3.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
                            4.4.1.4. Density-based Separation (Label-free)
                                4.4.1.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
                            4.4.1.5. Combined Methods
                                4.4.1.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
                        4.4.2. CTC Direct Detection Methods
                            4.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
                            4.4.2.2. SERS
                                4.4.2.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
                            4.4.2.3. Microscopy
                                4.4.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
                            4.4.2.4. Others
                                4.4.2.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
                        4.4.3. CTC Analysis
                            4.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 5. Circulating Tumor Cells Market: Application Estimates & Trend Analysis
                    5.1. Application Segment Dashboard
                    5.2. Global Circulating Tumor Cells Market Application Movement Analysis
                    5.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
                    5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
                        5.4.1. Clinical
                            5.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
                            5.4.1.2. Risk Assessment
                                5.4.1.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
                            5.4.1.3. Screening and Monitoring
                                5.4.1.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
                        5.4.2. Research
                            5.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
                            5.4.2.2. Cancer Stem Cell & Tumorogenesis Research
                                5.4.2.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
                            5.4.2.3. Drug/Therapy Development
                                5.4.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 6. Circulating Tumor Cells Market: Product Estimates & Trend Analysis
                    6.1. Product Segment Dashboard
                    6.2. Global Circulating Tumor Cells Market Product Movement Analysis
                    6.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
                    6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
                        6.4.1. Kits & reagents
                            6.4.1.1. Market estimates and forecasts 2018 - 2030 (USD million)
                        6.4.2. Blood collection tubes
                            6.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
                        6.4.3. Devices or systems
                            6.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 7. Circulating Tumor Cells Market: Specimen Estimates & Trend Analysis
                    7.1. Specimen Segment Dashboard
                    7.2. Global Circulating Tumor Cells Market Specimen Movement Analysis
                    7.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Specimen, 2018 to 2030 (USD Million)
                    7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
                        7.4.1. Blood
                            7.4.1.1. Market estimates and forecasts 2018 - 2030 (USD million)
                        7.4.2. Bone marrow
                            7.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
                        7.4.3. Other body fluids
                            7.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 8. Circulating Tumor Cells Market: End Use Estimates & Trend Analysis
                    8.1. End Use Segment Dashboard
                    8.2. Global Circulating Tumor Cells Market End Use Movement Analysis
                    8.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
                    8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
                        8.4.1. Research and academic institutes
                            8.4.1.1. Market estimates and forecasts 2018 - 2030 (USD million)
                        8.4.2. Hospital and clinics
                            8.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
                        8.4.3. Diagnostic centers
                            8.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 9. Circulating Tumor Cells Market: Regional Estimates & Trend Analysis
                    9.1. Regional Market Share Analysis, 2024 & 2030
                    9.2. Regional Market Dashboard
                    9.3. North America
                        9.3.1. U.S.
                            9.3.1.1. Key country dynamics
                            9.3.1.2. Regulatory framework
                            9.3.1.3. Competitive scenario
                            9.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
                            9.3.1.5. Target disease prevalence
                        9.3.2. Canada
                            9.3.2.1. Key country dynamics
                            9.3.2.2. Regulatory framework
                            9.3.2.3. Competitive scenario
                            9.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
                            9.3.2.5. Target disease prevalence
                        9.3.3. Mexico
                            9.3.3.1. Key country dynamics
                            9.3.3.2. Regulatory framework
                            9.3.3.3. Competitive scenario
                            9.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
                            9.3.3.5. Target disease prevalence
                    9.4. Europe
                        9.4.1. UK
                            9.4.1.1. Key country dynamics
                            9.4.1.2. Regulatory framework
                            9.4.1.3. Competitive scenario
                            9.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
                            9.4.1.5. Target disease prevalence
                        9.4.2. Germany
                            9.4.2.1. Key country dynamics
                            9.4.2.2. Regulatory framework
                            9.4.2.3. Competitive scenario
                            9.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
                            9.4.2.5. Target disease prevalence
                        9.4.3. France
                            9.4.3.1. Key country dynamics
                            9.4.3.2. Regulatory framework
                            9.4.3.3. Competitive scenario
                            9.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
                            9.4.3.5. Target disease prevalence
                        9.4.4. Italy
                            9.4.4.1. Key country dynamics
                            9.4.4.2. Regulatory framework
                            9.4.4.3. Competitive scenario
                            9.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
                            9.4.4.5. Target disease prevalence
                        9.4.5. Spain
                            9.4.5.1. Key country dynamics
                            9.4.5.2. Regulatory framework
                            9.4.5.3. Competitive scenario
                            9.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
                            9.4.5.5. Target disease prevalence
                        9.4.6. Norway
                            9.4.6.1. Key country dynamics
                            9.4.6.2. Regulatory framework
                            9.4.6.3. Competitive scenario
                            9.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
                            9.4.6.5. Target disease prevalence
                        9.4.7. Sweden
                            9.4.7.1. Key country dynamics
                            9.4.7.2. Regulatory framework
                            9.4.7.3. Competitive scenario
                            9.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
                            9.4.7.5. Target disease prevalence
                        9.4.8. Denmark
                            9.4.8.1. Key country dynamics
                            9.4.8.2. Regulatory framework
                            9.4.8.3. Competitive scenario
                            9.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
                            9.4.8.5. Target disease prevalence
                    9.5. Asia Pacific
                        9.5.1. Japan
                            9.5.1.1. Key country dynamics
                            9.5.1.2. Regulatory framework
                            9.5.1.3. Competitive scenario
                            9.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
                            9.5.1.5. Target disease prevalence
                        9.5.2. China
                            9.5.2.1. Key country dynamics
                            9.5.2.2. Regulatory framework
                            9.5.2.3. Competitive scenario
                            9.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
                            9.5.2.5. Target disease prevalence
                        9.5.3. India
                            9.5.3.1. Key country dynamics
                            9.5.3.2. Regulatory framework
                            9.5.3.3. Competitive scenario
                            9.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
                            9.5.3.5. Target disease prevalence
                        9.5.4. Australia
                            9.5.4.1. Key country dynamics
                            9.5.4.2. Regulatory framework
                            9.5.4.3. Competitive scenario
                            9.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
                            9.5.4.5. Target disease prevalence
                        9.5.5. South Korea
                            9.5.5.1. Key country dynamics
                            9.5.5.2. Regulatory framework
                            9.5.5.3. Competitive scenario
                            9.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
                            9.5.5.5. Target disease prevalence
                        9.5.6. Thailand
                            9.5.6.1. Key country dynamics
                            9.5.6.2. Regulatory framework
                            9.5.6.3. Competitive scenario
                            9.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
                            9.5.6.5. Target disease prevalence
                    9.6. Latin America
                        9.6.1. Brazil
                            9.6.1.1. Key country dynamics
                            9.6.1.2. Regulatory framework
                            9.6.1.3. Competitive scenario
                            9.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
                            9.6.1.5. Target disease prevalence
                        9.6.2. Argentina
                            9.6.2.1. Key country dynamics
                            9.6.2.2. Regulatory framework
                            9.6.2.3. Competitive scenario
                            9.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
                            9.6.2.5. Target disease prevalence
                    9.7. MEA
                        9.7.1. South Africa
                            9.7.1.1. Key country dynamics
                            9.7.1.2. Regulatory framework
                            9.7.1.3. Competitive scenario
                            9.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
                            9.7.1.5. Target disease prevalence
                        9.7.2. Saudi Arabia
                            9.7.2.1. Key country dynamics
                            9.7.2.2. Regulatory framework
                            9.7.2.3. Competitive scenario
                            9.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
                            9.7.2.5. Target disease prevalence
                        9.7.3. UAE
                            9.7.3.1. Key country dynamics
                            9.7.3.2. Regulatory framework
                            9.7.3.3. Competitive scenario
                            9.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
                            9.7.3.5. Target disease prevalence
                        9.7.4. Kuwait
                            9.7.4.1. Key country dynamics
                            9.7.4.2. Regulatory framework
                            9.7.4.3. Competitive scenario
                            9.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)
                            9.7.4.5. Target disease prevalence
Chapter 10. Competitive Landscape
                    10.1. Recent Developments & Impact Analysis, By Key Market Participants
                    10.2. Company/Competition Categorization
                    10.3. Vendor Landscape
                        10.3.1. List of key distributors and channel partners
                        10.3.2. Key customers
                        10.3.3. Key company position analysis, 2024
                        10.3.4. QIAGEN
                            10.3.4.1. Company overview
                            10.3.4.2. Financial performance
                            10.3.4.3. Product benchmarking
                            10.3.4.4. Strategic initiatives
                        10.3.5. Bio-Techne Corp.
                            10.3.5.1. Company overview
                            10.3.5.2. Financial performance
                            10.3.5.3. Product benchmarking
                            10.3.5.4. Strategic initiatives
                        10.3.6. Precision Medicine Group, LLC.
                            10.3.6.1. Company overview
                            10.3.6.2. Financial performance
                            10.3.6.3. Product benchmarking
                            10.3.6.4. Strategic initiatives
                        10.3.7. Bio-Rad Laboratories, Inc.
                            10.3.7.1. Company overview
                            10.3.7.2. Financial performance
                            10.3.7.3. Product benchmarking
                            10.3.7.4. Strategic initiatives
                        10.3.8. Natera, Inc.
                            10.3.8.1. Company overview
                            10.3.8.2. Financial performance
                            10.3.8.3. Product benchmarking
                            10.3.8.4. Strategic initiatives
                        10.3.9. Illumina, Inc.
                            10.3.9.1. Company overview
                            10.3.9.2. Financial performance
                            10.3.9.3. Product benchmarking
                            10.3.9.4. Strategic initiatives
                        10.3.10. Cell Microsystems
                            10.3.10.1. Company overview
                            10.3.10.2. Financial performance
                            10.3.10.3. Product benchmarking
                            10.3.10.4. Strategic initiatives
                        10.3.11. Greiner Bio One International GmbH
                            10.3.11.1. Company overview
                            10.3.11.2. Financial performance
                            10.3.11.3. Product benchmarking
                            10.3.11.4. Strategic initiatives
                        10.3.12. Ikonisys Inc.
                            10.3.12.1. Company overview
                            10.3.12.2. Financial performance
                            10.3.12.3. Product benchmarking
                            10.3.12.4. Strategic initiatives
                        10.3.13. Miltenyi Biotec
                            10.3.13.1. Company overview
                            10.3.13.2. Financial performance
                            10.3.13.3. Product benchmarking
                            10.3.13.4. Strategic initiatives
                        10.3.14. Creative Bioarray
                            10.3.14.1. Company overview
                            10.3.14.2. Financial performance
                            10.3.14.3. Product benchmarking
                            10.3.14.4. Strategic initiatives
                        10.3.15. BioFluidica
                            10.3.15.1. Company overview
                            10.3.15.2. Financial performance
                            10.3.15.3. Product benchmarking
                            10.3.15.4. Strategic initiatives
                        10.3.16. Abnova Corporation
                            10.3.16.1. Company overview
                            10.3.16.2. Financial performance
                            10.3.16.3. Product benchmarking
                            10.3.16.4. Strategic initiatives
                        10.3.17. Biolidics Limited
                            10.3.17.1. Company overview
                            10.3.17.2. Financial performance
                            10.3.17.3. Product benchmarking
                            10.3.17.4. Strategic initiatives
                        10.3.18. Creativ MicroTech, Inc.
                            10.3.18.1. Company overview
                            10.3.18.2. Financial performance
                            10.3.18.3. Product benchmarking
                            10.3.18.4. Strategic initiatives
                        10.3.19. LungLife AI
                            10.3.19.1. Company overview
                            10.3.19.2. Financial performance
                            10.3.19.3. Product benchmarking
                            10.3.19.4. Strategic initiatives
                        10.3.20. Epic Sciences
                            10.3.20.1. Company overview
                            10.3.20.2. Financial performance
                            10.3.20.3. Product benchmarking
                            10.3.20.4. Strategic initiatives
                        10.3.21. Rarecells Diagnostics
                            10.3.21.1. Company overview
                            10.3.21.2. Financial performance
                            10.3.21.3. Product benchmarking
                            10.3.21.4. Strategic initiatives
                        10.3.22. ScreenCell
                            10.3.22.1. Company overview
                            10.3.22.2. Financial performance
                            10.3.22.3. Product benchmarking
                            10.3.22.4. Strategic initiatives
                        10.3.23. Menarini Silicon Biosystems
                            10.3.23.1. Company overview
                            10.3.23.2. Financial performance
                            10.3.23.3. Product benchmarking
                            10.3.23.4. Strategic initiatives
                        10.3.24. APPLIED DNA SCIENCES, INC.
                            10.3.24.1. Company overview
                            10.3.24.2. Financial performance
                            10.3.24.3. Product benchmarking
                            10.3.24.4. Strategic initiatives
                        10.3.25. Sysmex Corporation
                            10.3.25.1. Company overview
                            10.3.25.2. Financial performance
                            10.3.25.3. Product benchmarking
                            10.3.25.4. Strategic initiatives
                        10.3.26. STEMCELL Technologies, Inc.
                            10.3.26.1. Company overview
                            10.3.26.2. Financial performance
                            10.3.26.3. Product benchmarking
                            10.3.26.4. Strategic initiatives


List of Tables

Table 1 List of abbreviation
Table 2 North America circulating tumor cells market, by region, 2018 - 2030 (USD Million)
Table 3 North America circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 4 North America circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 5 North America circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 6 North America circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 7 North America circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 8 U.S. circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 9 U.S. circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 10 U.S. circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 11 U.S. circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 12 U.S. circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 13 Canada circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 14 Canada circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 15 Canada circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 16 Canada circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 17 Canada circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 18 Mexico circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 19 Mexico circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 20 Mexico circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 21 Mexico circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 22 Mexico circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 23 Europe circulating tumor cells market, by region, 2018 - 2030 (USD Million)
Table 24 Europe circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 25 Europe circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 26 Europe circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 27 Europe circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 28 Europe circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 29 UK circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 30 UK circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 31 UK circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 32 UK circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 33 UK circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 34 Germany circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 35 Germany circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 36 Germany circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 37 Germany circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 38 Germany circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 39 Italy circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 40 Italy circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 41 Italy circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 42 Italy circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 43 Italy circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 44 France circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 45 France circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 46 France circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 47 France circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 48 France circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 49 Spain circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 50 Spain circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 51 Spain circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 52 Spain circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 53 Spain circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 54 Sweden circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 55 Sweden circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 56 Sweden circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 57 Sweden circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 58 Sweden circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 59 Denmark circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 60 Denmark circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 61 Denmark circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 62 Denmark circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 63 Denmark circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 64 Norway circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 65 Norway circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 66 Norway circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 67 Norway circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 68 Norway circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 69 Asia Pacific circulating tumor cells market, by region, 2018 - 2030 (USD Million)
Table 70 Asia Pacific circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 71 Asia Pacific circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 72 Asia Pacific circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 73 Asia Pacific circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 74 Asia Pacific circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 75 China circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 76 China circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 77 China circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 78 China circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 79 China circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 80 Japan circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 81 Japan circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 82 Japan circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 83 Japan circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 84 Japan circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 85 India circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 86 India circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 87 India circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 88 India circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 89 India circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 90 South Korea circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 91 South Korea circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 92 South Korea circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 93 South Korea circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 94 South Korea circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 95 Australia circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 96 Australia circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 97 Australia circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 98 Australia circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 99 Australia circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 100 Thailand circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 101 Thailand circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 102 Thailand circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 103 Thailand circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 104 Thailand circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 105 Latin America circulating tumor cells market, by region, 2018 - 2030 (USD Million)
Table 106 Latin America circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 107 Latin America circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 108 Latin America circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 109 Latin America circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 110 Latin America circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 111 Brazil circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 112 Brazil circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 113 Brazill circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 114 Brazil circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 115 Brazil circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 116 Argentina circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 117 Argentina circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 118 Argentina circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 119 Argentina circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 120 Argentina circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 121 Middle East Africa circulating tumor cells market, by region, 2018 - 2030 (USD Million)
Table 122 Middle East Africa circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 123 Middle East Africa circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 124 Middle East Africa circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 125 Middle East Africa circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 126 Middle East Africa circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 127 South Africa circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 128 South Africa circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 129 South Africa circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 130 South Africa circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 131 South Africa circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 132 Saudi Arabia circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 133 Saudi Arabia circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 134 Saudi Arabia circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 135 Saudi Arabia circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 136 Saudi Arabia circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 137 UAE circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 138 UAE circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 139 UAE circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 140 UAE circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 141 UAE circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 142 Kuwait circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 143 Kuwait circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 144 Kuwait circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 145 Kuwait circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 146 Kuwait circulating tumor cells market, by end use, 2018 - 2030 (USD Million)


List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Circulating tumor cells market: market outlook
Fig. 9 Circulating tumor cells competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Circulating tumor cells market driver impact
Fig. 15 Circulating tumor cells market restraint impact
Fig. 16 Circulating tumor cells market strategic initiatives analysis
Fig. 17 Circulating tumor cells market: Technology movement analysis
Fig. 18 Circulating tumor cells market: Technology outlook and key takeaways
Fig. 19 CTC detection & enrichment methods market estimates and forecast, 2018 - 2030
Fig. 20 Immunocapture (label-based) estimates and forecast, 2018 - 2030
Fig. 21 Positive selection market estimates and forecast, 2018 - 2030
Fig. 22 Negative selection estimates and forecast, 2018 - 2030
Fig. 23 Size-based separation (label-free) market estimates and forecast, 2018 - 2030
Fig. 24 Membrane-based estimates and forecast, 2018 - 2030
Fig. 25 Microfluidic-based estimates and forecast, 2018 - 2030
Fig. 26 Density-based Separation (Label-free) estimates and forecast, 2018 - 2030
Fig. 27 Combined Methods estimates and forecast, 2018 - 2030
Fig. 28 CTC direct detection methods estimates and forecast, 2018 - 2030
Fig. 29 SERS estimates and forecast, 2018 - 2030
Fig. 30 Microscopy estimates and forecast, 2018 - 2030
Fig. 31 Others estimates and forecast, 2018 - 2030
Fig. 32 CTC Analysis estimates and forecast, 2018 - 2030
Fig. 33 Circulating tumor cells Market: Application movement Analysis
Fig. 34 Circulating tumor cells market: Application outlook and key takeaways
Fig. 35 Clinical/ Liquid Biopsy market estimates and forecasts, 2018 - 2030
Fig. 36 Risk Assessment market estimates and forecasts, 2018 - 2030
Fig. 37 Screening and Monitoring market estimates and forecasts, 2018 - 2030
Fig. 38 Research market estimates and forecasts, 2018 - 2030
Fig. 39 Cancer Stem Cell & Tumorogenesis Research market estimates and forecasts, 2018 - 2030
Fig. 40 Drug/Therapy Development market estimates and forecasts, 2018 - 2030
Fig. 41 Circulating tumor cells Market: Product movement Analysis
Fig. 42 Circulating tumor cells market: Product outlook and key takeaways
Fig. 43 Kits & reagents market estimates and forecasts, 2018 - 2030
Fig. 44 Blood collection tubes market estimates and forecasts, 2018 - 2030
Fig. 45 Devices or Systems market estimates and forecasts, 2018 - 2030
Fig. 46 Circulating tumor cells Market: Specimen movement Analysis
Fig. 47 Circulating tumor cells market: Specimen outlook and key takeaways
Fig. 48 Blood market estimates and forecasts, 2018 - 2030
Fig. 49 Bone marrow market estimates and forecasts, 2018 - 2030
Fig. 50 Other body fluids market estimates and forecasts, 2018 - 2030
Fig. 51 Circulating tumor cells Market: End use movement Analysis
Fig. 52 Circulating tumor cells market: End use outlook and key takeaways
Fig. 53 Research and academic institutes market estimates and forecasts, 2018 - 2030
Fig. 54 Hospital and clinics market estimates and forecasts, 2018 - 2030
Fig. 55 Diagnostic centers market estimates and forecasts, 2018 - 2030
Fig. 56 Global circulating tumor cells market: Regional movement analysis
Fig. 57 Global circulating tumor cells market: Regional outlook and key takeaways
Fig. 58 North America, by country
Fig. 59 North America
Fig. 60 North America market estimates and forecasts, 2018 - 2030
Fig. 61 U.S. country dynamics
Fig. 62 U.S. market estimates and forecasts, 2018 - 2030
Fig. 63 Canada country dynamics
Fig. 64 Canada market estimates and forecasts, 2018 - 2030
Fig. 65 Mexico country dynamics
Fig. 66 Mexico market estimates and forecasts, 2018 - 2030
Fig. 67 Europe market estimates and forecasts, 2018 - 2030
Fig. 68 UK country dynamics
Fig. 69 UK market estimates and forecasts, 2018 - 2030
Fig. 70 Germany country dynamics
Fig. 71 Germany market estimates and forecasts, 2018 - 2030
Fig. 72 France country dynamics
Fig. 73 France market estimates and forecasts, 2018 - 2030
Fig. 74 Italy country dynamics
Fig. 75 Italy market estimates and forecasts, 2018 - 2030
Fig. 76 Spain country dynamics
Fig. 77 Spain market estimates and forecasts, 2018 - 2030
Fig. 78 Denmark country dynamics
Fig. 79 Denmark market estimates and forecasts, 2018 - 2030
Fig. 80 Sweden country dynamics
Fig. 81 Sweden market estimates and forecasts, 2018 - 2030
Fig. 82 Norway country dynamics
Fig. 83 Norway market estimates and forecasts, 2018 - 2030
Fig. 84 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 85 China country dynamics
Fig. 86 China market estimates and forecasts, 2018 - 2030
Fig. 87 Japan country dynamics
Fig. 88 Japan market estimates and forecasts, 2018 - 2030
Fig. 89 India country dynamics
Fig. 90 India market estimates and forecasts, 2018 - 2030
Fig. 91 Thailand country dynamics
Fig. 92 Thailand market estimates and forecasts, 2018 - 2030
Fig. 93 South Korea country dynamics
Fig. 94 South Korea market estimates and forecasts, 2018 - 2030
Fig. 95 Australia country dynamics
Fig. 96 Australia market estimates and forecasts, 2018 - 2030
Fig. 97 Latin America market estimates and forecasts, 2018 - 2030
Fig. 98 Brazil country dynamics
Fig. 99 Brazil market estimates and forecasts, 2018 - 2030
Fig. 100 Argentina country dynamics
Fig. 101 Argentina market estimates and forecasts, 2018 - 2030
Fig. 102 Middle East and Africa market estimates and forecasts, 2018 - 2030
Fig. 103 South Africa country dynamics
Fig. 104 South Africa market estimates and forecasts, 2018 - 2030
Fig. 105 Saudi Arabia country dynamics
Fig. 106 Saudi Arabia market estimates and forecasts, 2018 - 2030
Fig. 107 UAE country dynamics
Fig. 108 UAE market estimates and forecasts, 2018 - 2030
Fig. 109 Kuwait country dynamics
Fig. 110 Kuwait market estimates and forecasts, 2018 - 2030
Fig. 111 Market position of key market players- Circulating tumor cells market

What questions do you have? Get quick response from our industry experts. Request a Free Consultation

Market Segmentation

  • Circulating Tumor Cells Technology Outlook (Revenue, USD Million, 2018 - 2030)
    • CTC detection & enrichment methods
    • Immunocapture (label-based)
    • Positive selection
    • Negative selection
    • Size-based separation (label-free)
    • Membrane-based
    • Microfluidic-based
    • Density-based separation (label-free)
    • Combined methods
    • CTC Direct Detection Methods
    • SERS
    • Microscopy
    • Others
    • CTC Analysis
  • Circulating Tumor Cells Application Outlook (Revenue, USD Million, 2018 - 2030)
    • Clinical/ Liquid Biopsy
    • Risk Assessment
    • Screening and Monitoring
    • Research
    • Cancer stem cell & tumorogenesis research
    • Drug/therapy development
  • Circulating Tumor Cells Product Outlook (Revenue, USD Million, 2018 - 2030)
    • Kits & Reagents
    • Blood Collection Tubes
    • Devices or Systems
  • Circulating Tumor Cells Specimen Outlook (Revenue, USD Million, 2018 - 2030)
    • Blood
    • Bone Marrow
    • Other Body Fluids
  • Circulating Tumor Cells End Use Outlook (Revenue, USD Million, 2018 - 2030)
    • Research and academic institutes
    • Hospital and clinics
    • Diagnostic centers
  • Circulating Tumor Cells Regional Outlook (Revenue, USD Million, 2018 - 2030)
    • North America
      • North America Circulating Tumor Cells Market, By Technology
        • CTC detection & enrichment methods
          • Immunocapture (label-based)
            • Positive selection
            • Negative selection
          • Size-based separation (label-free)
            • Membrane-based
            • Microfluidic-based
          • Density-based separation (label-free)
          • Combined methods
        • CTC direct detection methods
          • SERS
          • Microscopy
          • Other
        • CTC analysis
      • North America Circulating Tumor Cells Market, By Application
        • Clinical/ liquid biopsy
          • Risk assessment
          • Screening and monitoring
        • Research
          • Cancer stem cell & tumorogenesis research
          • Drug/therapy development
      • North America Circulating Tumor Cells Market, By Product
        • Kits & reagents
        • Blood collection tubes
        • Devices or systems
      • North America Circulating Tumor Cells Market, By Specimen
        • Blood
        • Bone marrow
        • Other body fluids
      • North America Circulating Tumor Cells Market, By End Use
        • Research and academic institutes
        • Hospital and clinics
        • Diagnostic centers
      • U.S.
        • U.S. Circulating Tumor Cells Market, By Technology
          • CTC detection & enrichment methods
            • Immunocapture (label-based)
              • Positive selection
              • Negative selection
            • Size-based separation (label-free)
              • Membrane-based
              • Microfluidic-based
            • Density-based separation (label-free)
            • Combined methods
          • CTC direct detection methods
            • SERS
            • Microscopy
            • Others
          • CTC analysis
        • U.S. Circulating Tumor Cells Market, By Application
          • Clinical/ liquid biopsy
            • Risk assessment
            • Screening and monitoring
          • Research
            • Cancer stem cell & tumorogenesis research
            • Drug/therapy development
        • U.S. Circulating Tumor Cells Market, By Product
          • Kits & reagents
          • Blood collection tubes
          • Devices or systems
        • U.S. Circulating Tumor Cells Market, By Specimen
          • Blood
          • Bone marrow
          • Other body fluids
        • U.S. Circulating Tumor Cells Market, By End Use
          • Research and academic institutes
          • Hospital and clinics
          • Diagnostic centers
      • Canada
        • Canada Circulating Tumor Cells Market, By Technology
          • CTC detection & enrichment methods
            • Immunocapture (label-based)
              • Positive selection
              • Negative selection
            • Size-based separation (label-free)
              • Membrane-based
              • Microfluidic-based
            • Density-based separation (label-free)
            • Combined methods
          • CTC direct detection methods
            • SERS
            • Microscopy
            • Others
          • CTC analysis
        • Canada Circulating Tumor Cells Market, By Application
          • Clinical/ liquid biopsy
            • Risk assessment
            • Screening and monitoring
          • Research
            • Cancer stem cell & tumorogenesis research
            • Drug/therapy development
        • Canada Circulating Tumor Cells Market, By Product
          • Kits & reagents
          • Blood collection tubes
          • Devices or systems
        • Canada Circulating Tumor Cells Market, By Specimen
          • Blood
          • Bone marrow
          • Other body fluids
        • Canada Circulating Tumor Cells Market, By End Use
          • Research and academic institutes
          • Hospital and clinics
          • Diagnostic centers
      • Mexico
        • Mexico Circulating Tumor Cells Market, By Technology
          • CTC detection & enrichment methods
            • Immunocapture (label-based)
              • Positive selection
              • Negative selection
            • Size-based separation (label-free)
              • Membrane-based
              • Microfluidic-based
            • Density-based separation (label-free)
            • Combined methods
          • CTC direct detection methods
            • SERS
            • Microscopy
            • Others
          • CTC analysis
        • Mexico Circulating Tumor Cells Market, By Application
          • Clinical/ liquid biopsy
            • Risk assessment
            • Screening and monitoring
          • Research
            • Cancer stem cell & tumorogenesis research
            • Drug/therapy development
        • Mexico Circulating Tumor Cells Market, By Product
          • Kits & reagents
          • Blood collection tubes
          • Devices or systems
        • Mexico Circulating Tumor Cells Market, By Specimen
          • Blood
          • Bone marrow
          • Other body fluids
        • Mexico Circulating Tumor Cells Market, By End Use
          • Research and academic institutes
          • Hospital and clinics
          • Diagnostic centers
    • Europe
      • Europe Circulating Tumor Cells Market, By Technology
        • CTC detection & enrichment methods
          • Immunocapture (label-based)
            • Positive selection
            • Negative selection
          • Size-based separation (label-free)
            • Membrane-based
            • Microfluidic-based
          • Density-based separation (label-free)
          • Combined methods
        • CTC direct detection methods
          • SERS
          • Microscopy
          • Other
        • CTC analysis
      • Europe Circulating Tumor Cells Market, By Application
        • Clinical/ liquid biopsy
          • Risk assessment
          • Screening and monitoring
        • Research
          • Cancer stem cell & tumorogenesis research
          • Drug/therapy development
      • Europe Circulating Tumor Cells Market, By Product
        • Kits & reagents
        • Blood collection tubes
        • Devices or systems
      • Europe Specimen Outlook (Revenue in USD Million, 2018 - 2030)
        • Blood
        • Bone marrow
        • Other body fluids
      • Europe End use Outlook (Revenue in USD Million, 2018 - 2030)
        • Research and academic institutes
        • Hospital and clinics
        • Diagnostic centers
      • UK
        • UK Circulating Tumor Cells Market, By Technology
          • CTC detection & enrichment methods
            • Immunocapture (label-based)
              • Positive selection
              • Negative selection
            • Size-based separation (label-free)
              • Membrane-based
              • Microfluidic-based
            • Density-based separation (label-free)
            • Combined methods
          • CTC direct detection methods
            • SERS
            • Microscopy
            • Others
          • CTC analysis
        • UK Circulating Tumor Cells Market, By Application
          • Clinical/ liquid biopsy
            • Risk assessment
            • Screening and monitoring
          • Research
            • Cancer stem cell & tumorogenesis research
            • Drug/therapy development
        • UK Circulating Tumor Cells Market, By Product
          • Kits & reagents
          • Blood collection tubes
          • Devices or systems
        • UK Specimen Outlook (Revenue in USD Million, 2018 - 2030)
          • Blood
          • Bone marrow
          • Other body fluids
        • UK End use Outlook (Revenue in USD Million, 2018 - 2030)
          • Research and academic institutes
          • Hospital and clinics
          • Diagnostic centers
      • Germany
        • Germany Circulating Tumor Cells Market, By Technology
          • CTC detection & enrichment methods
            • Immunocapture (label-based)
              • Positive selection
              • Negative selection
            • Size-based separation (label-free)
              • Membrane-based
              • Microfluidic-based
            • Density-based separation (label-free)
            • Combined methods
          • CTC direct detection methods
            • SERS
            • Microscopy
            • Others
          • CTC analysis
        • Germany Circulating Tumor Cells Market, By Application
          • Clinical/ liquid biopsy
            • Risk assessment
            • Screening and monitoring
          • Research
            • Cancer stem cell & tumorogenesis research
            • Drug/therapy development
        • Germany Circulating Tumor Cells Market, By Product
          • Kits & reagents
          • Blood collection tubes
          • Devices or systems
        • Germany Specimen Outlook (Revenue in USD Million, 2018 - 2030)
          • Blood
          • Bone marrow
          • Other body fluids
        • Germany End use Outlook (Revenue in USD Million, 2018 - 2030)
          • Research and academic institutes
          • Hospital and clinics
          • Diagnostic centers
      • France
        • France Circulating Tumor Cells Market, By Technology
          • CTC detection & enrichment methods
            • Immunocapture (label-based)
              • Positive selection
              • Negative selection
            • Size-based separation (label-free)
              • Membrane-based
              • Microfluidic-based
            • Density-based separation (label-free)
            • Combined methods
          • CTC direct detection methods
            • SERS
            • Microscopy
            • Others
          • CTC analysis
        • France Circulating Tumor Cells Market, By Application
          • Clinical/ liquid biopsy
            • Risk assessment
            • Screening and monitoring
          • Research
            • Cancer stem cell & tumorogenesis research
            • Drug/therapy development
        • France Circulating Tumor Cells Market, By Product
          • Kits & reagents
          • Blood collection tubes
          • Devices or systems
        • France Specimen Outlook (Revenue in USD Million, 2018 - 2030)
          • Blood
          • Bone marrow
          • Other body fluids
        • France End use Outlook (Revenue in USD Million, 2018 - 2030)
          • Research and academic institutes
          • Hospital and clinics
          • Diagnostic centers
      • Italy
        • Italy Circulating Tumor Cells Market, By Technology
          • CTC detection & enrichment methods
            • Immunocapture (label-based)
              • Positive selection
              • Negative selection
            • Size-based separation (label-free)
              • Membrane-based
              • Microfluidic-based
            • Density-based separation (label-free)
            • Combined methods
          • CTC direct detection methods
            • SERS
            • Microscopy
            • Others
          • CTC analysis
        • Italy Circulating Tumor Cells Market, By Application
          • Clinical/ liquid biopsy
            • Risk assessment
            • Screening and monitoring
          • Research
            • Cancer stem cell & tumorogenesis research
            • Drug/therapy development
        • Italy Circulating Tumor Cells Market, By Product
          • Kits & reagents
          • Blood collection tubes
          • Devices or systems
        • Italy Circulating Tumor Cells Market, By Specimen
          • Blood
          • Bone marrow
          • Other body fluids
        • Italy Circulating Tumor Cells Market, By End Use
          • Research and academic institutes
          • Hospital and clinics
          • Diagnostic centers
      • Spain
        • Spain Circulating Tumor Cells Market, By Technology
          • CTC detection & enrichment methods
            • Immunocapture (label-based)
              • Positive selection
              • Negative selection
            • Size-based separation (label-free)
              • Membrane-based
              • Microfluidic-based
            • Density-based separation (label-free)
            • Combined methods
          • CTC direct detection methods
            • SERS
            • Microscopy
            • Others
          • CTC analysis
        • Spain Circulating Tumor Cells Market, By Application
          • Clinical/ liquid biopsy
            • Risk assessment
            • Screening and monitoring
          • Research
            • Cancer stem cell & tumorogenesis research
            • Drug/therapy development
        • Spain Circulating Tumor Cells Market, By Product
          • Kits & reagents
          • Blood collection tubes
          • Devices or systems
        • Spain Circulating Tumor Cells Market, By Specimen
          • Blood
          • Bone marrow
          • Other body fluids
        • Spain Circulating Tumor Cells Market, By End Use
          • Research and academic institutes
          • Hospital and clinics
          • Diagnostic centers
      • Sweden
        • Sweden Circulating Tumor Cells Market, By Technology
          • CTC detection & enrichment methods
            • Immunocapture (label-based)
              • Positive selection
              • Negative selection
            • Size-based separation (label-free)
              • Membrane-based
              • Microfluidic-based
            • Density-based separation (label-free)
            • Combined methods
          • CTC direct detection methods
            • SERS
            • Microscopy
            • Others
          • CTC analysis
        • Sweden Circulating Tumor Cells Market, By Application
          • Clinical/ liquid biopsy
            • Risk assessment
            • Screening and monitoring
          • Research
            • Cancer stem cell & tumorogenesis research
            • Drug/therapy development
        • Sweden Circulating Tumor Cells Market, By Product
          • Kits & reagents
          • Blood collection tubes
          • Devices or systems
        • Sweden Circulating Tumor Cells Market, By Specimen
          • Blood
          • Bone marrow
          • Other body fluids
        • Sweden Circulating Tumor Cells Market, By End Use
          • Research and academic institutes
          • Hospital and clinics
          • Diagnostic centers
      • Denmark
        • Denmark Circulating Tumor Cells Market, By Technology
          • CTC detection & enrichment methods
            • Immunocapture (label-based)
              • Positive selection
              • Negative selection
            • Size-based separation (label-free)
              • Membrane-based
              • Microfluidic-based
            • Density-based separation (label-free)
            • Combined methods
          • CTC direct detection methods
            • SERS
            • Microscopy
            • Others
          • CTC analysis
        • Denmark Circulating Tumor Cells Market, By Application
          • Clinical/ liquid biopsy
            • Risk assessment
            • Screening and monitoring
          • Research
            • Cancer stem cell & tumorogenesis research
            • Drug/therapy development
        • Denmark Circulating Tumor Cells Market, By Product
          • Kits & reagents
          • Blood collection tubes
          • Devices or systems
        • Denmark Circulating Tumor Cells Market, By Specimen
          • Blood
          • Bone marrow
          • Other body fluids
        • Denmark Circulating Tumor Cells Market, By End Use
          • Research and academic institutes
          • Hospital and clinics
          • Diagnostic centers
      • Norway
        • Norway Circulating Tumor Cells Market, By Technology
          • CTC detection & enrichment methods
            • Immunocapture (label-based)
              • Positive selection
              • Negative selection
            • Size-based separation (label-free)
              • Membrane-based
              • Microfluidic-based
            • Density-based separation (label-free)
            • Combined methods
          • CTC direct detection methods
            • SERS
            • Microscopy
            • Others
          • CTC analysis
        • Norway Circulating Tumor Cells Market, By Application
          • Clinical/ liquid biopsy
            • Risk assessment
            • Screening and monitoring
          • Research
            • Cancer stem cell & tumorogenesis research
            • Drug/therapy development
        • Norway Circulating Tumor Cells Market, By Product
          • Kits & reagents
          • Blood collection tubes
          • Devices or systems
        • Norway Circulating Tumor Cells Market, By Specimen
          • Blood
          • Bone marrow
          • Other body fluids
        • Norway Circulating Tumor Cells Market, By End Use
          • Research and academic institutes
          • Hospital and clinics
          • Diagnostic centers
    • Asia Pacific
      • Asia Pacific Circulating Tumor Cells Market, By Technology
        • CTC detection & enrichment methods
          • Immunocapture (label-based)
            • Positive selection
            • Negative selection
          • Size-based separation (label-free)
            • Membrane-based
            • Microfluidic-based
          • Density-based separation (label-free)
          • Combined methods
        • CTC direct detection methods
          • SERS
          • Microscopy
          • Other
        • CTC analysis
      • Asia Pacific Circulating Tumor Cells Market, By Application
        • Clinical/ liquid biopsy
          • Risk assessment
          • Screening and monitoring
        • Research
          • Cancer stem cell & tumorogenesis research
          • Drug/therapy development
      • Asia Pacific Circulating Tumor Cells Market, By Product
        • Kits & reagents
        • Blood collection tubes
        • Devices or systems
      • Asia Pacific Circulating Tumor Cells Market, By Specimen
        • Blood
        • Bone marrow
        • Other body fluids
      • Asia Pacific Circulating Tumor Cells Market, By End Use
        • Research and academic institutes
        • Hospital and clinics
        • Diagnostic centers
      • China
        • China Circulating Tumor Cells Market, By Technology
          • CTC detection & enrichment methods
            • Immunocapture (label-based)
              • Positive selection
              • Negative selection
            • Size-based separation (label-free)
              • Membrane-based
              • Microfluidic-based
            • Density-based separation (label-free)
            • Combined methods
          • CTC direct detection methods
            • SERS
            • Microscopy
            • Others
          • CTC analysis
        • China Circulating Tumor Cells Market, By Application
          • Clinical/ liquid biopsy
            • Risk assessment
            • Screening and monitoring
          • Research
            • Cancer stem cell & tumorogenesis research
            • Drug/therapy development
        • China Circulating Tumor Cells Market, By Product
          • Kits & reagents
          • Blood collection tubes
          • Devices or systems
        • China Circulating Tumor Cells Market, By Specimen
          • Blood
          • Bone marrow
          • Other body fluids
        • China Circulating Tumor Cells Market, By End Use
          • Research and academic institutes
          • Hospital and clinics
          • Diagnostic centers
      • Japan
        • Japan Circulating Tumor Cells Market, By Technology
          • CTC detection & enrichment methods
            • Immunocapture (label-based)
              • Positive selection
              • Negative selection
            • Size-based separation (label-free)
              • Membrane-based
              • Microfluidic-based
            • Density-based separation (label-free)
            • Combined methods
          • CTC direct detection methods
            • SERS
            • Microscopy
            • Others
          • CTC analysis
        • Japan Circulating Tumor Cells Market, By Application
          • Clinical/ liquid biopsy
            • Risk assessment
            • Screening and monitoring
          • Research
            • Cancer stem cell & tumorogenesis research
            • Drug/therapy development
        • Japan Circulating Tumor Cells Market, By Product
          • Kits & reagents
          • Blood collection tubes
          • Devices or systems
        • Japan Circulating Tumor Cells Market, By Specimen
          • Blood
          • Bone marrow
          • Other body fluids
        • Japan Circulating Tumor Cells Market, By End Use
          • Research and academic institutes
          • Hospital and clinics
          • Diagnostic centers
      • India
        • India Circulating Tumor Cells Market, By Technology
          • CTC detection & enrichment methods
            • Immunocapture (label-based)
              • Positive selection
              • Negative selection
            • Size-based separation (label-free)
              • Membrane-based
              • Microfluidic-based
            • Density-based separation (label-free)
            • Combined methods
          • CTC direct detection methods
            • SERS
            • Microscopy
            • Others
          • CTC analysis
        • India Circulating Tumor Cells Market, By Application
          • Clinical/ liquid biopsy
            • Risk assessment
            • Screening and monitoring
          • Research
            • Cancer stem cell & tumorogenesis research
            • Drug/therapy development
        • India Circulating Tumor Cells Market, By Product
          • Kits & reagents
          • Blood collection tubes
          • Devices or systems
        • India Circulating Tumor Cells Market, By Specimen
          • Blood
          • Bone marrow
          • Other body fluids
        • India Circulating Tumor Cells Market, By End Use
          • Research and academic institutes
          • Hospital and clinics
          • Diagnostic centers
      • South Korea
        • South Korea Circulating Tumor Cells Market, By Technology
          • CTC detection & enrichment methods
            • Immunocapture (label-based)
              • Positive selection
              • Negative selection
            • Size-based separation (label-free)
              • Membrane-based
              • Microfluidic-based
            • Density-based separation (label-free)
            • Combined methods
          • CTC direct detection methods
            • SERS
            • Microscopy
            • Others
          • CTC analysis
        • South Korea Circulating Tumor Cells Market, By Application
          • Clinical/ liquid biopsy
            • Risk assessment
            • Screening and monitoring
          • Research
            • Cancer stem cell & tumorogenesis research
            • Drug/therapy development
        • South Korea Circulating Tumor Cells Market, By Product
          • Kits & reagents
          • Blood collection tubes
          • Devices or systems
        • South Korea Circulating Tumor Cells Market, By Specimen
          • Blood
          • Bone marrow
          • Other body fluids
        • South Korea Circulating Tumor Cells Market, By End Use
          • Research and academic institutes
          • Hospital and clinics
          • Diagnostic centers
      • Australia
        • Australia Circulating Tumor Cells Market, By Technology
          • CTC detection & enrichment methods
            • Immunocapture (label-based)
              • Positive selection
              • Negative selection
            • Size-based separation (label-free)
              • Membrane-based
              • Microfluidic-based
            • Density-based separation (label-free)
            • Combined methods
          • CTC direct detection methods
            • SERS
            • Microscopy
            • Others
          • CTC analysis
        • Australia Circulating Tumor Cells Market, By Application
          • Clinical/ liquid biopsy
            • Risk assessment
            • Screening and monitoring
          • Research
            • Cancer stem cell & tumorogenesis research
            • Drug/therapy development
        • Australia Circulating Tumor Cells Market, By Product
          • Kits & reagents
          • Blood collection tubes
          • Devices or systems
        • Australia Circulating Tumor Cells Market, By Specimen
          • Blood
          • Bone marrow
          • Other body fluids
        • Australia Circulating Tumor Cells Market, By End Use
          • Research and academic institutes
          • Hospital and clinics
          • Diagnostic centers
      • Thailand
        • Thailand Circulating Tumor Cells Market, By Technology
          • CTC detection & enrichment methods
            • Immunocapture (label-based)
              • Positive selection
              • Negative selection
            • Size-based separation (label-free)
              • Membrane-based
              • Microfluidic-based
            • Density-based separation (label-free)
            • Combined methods
          • CTC direct detection methods
            • SERS
            • Microscopy
            • Others
          • CTC analysis
        • Thailand Circulating Tumor Cells Market, By Application
          • Clinical/ liquid biopsy
            • Risk assessment
            • Screening and monitoring
          • Research
            • Cancer stem cell & tumorogenesis research
            • Drug/therapy development
        • Thailand Circulating Tumor Cells Market, By Product
          • Kits & reagents
          • Blood collection tubes
          • Devices or systems
        • Thailand Circulating Tumor Cells Market, By Specimen
          • Blood
          • Bone marrow
          • Other body fluids
        • Thailand Circulating Tumor Cells Market, By End Use
          • Research and academic institutes
          • Hospital and clinics
          • Diagnostic centers
    • Latin America
      • Latin America Circulating Tumor Cells Market, By Technology
        • CTC detection & enrichment methods
          • Immunocapture (label-based)
            • Positive selection
            • Negative selection
          • Size-based separation (label-free)
            • Membrane-based
            • Microfluidic-based
          • Density-based separation (label-free)
          • Combined methods
        • CTC direct detection methods
          • SERS
          • Microscopy
          • Other
        • CTC analysis
      • Latin America Circulating Tumor Cells Market, By Application
        • Clinical/ liquid biopsy
          • Risk assessment
          • Screening and monitoring
        • Research
          • Cancer stem cell & tumorogenesis research
          • Drug/therapy development
      • Latin America Circulating Tumor Cells Market, By Product
        • Kits & reagents
        • Blood collection tubes
        • Devices or systems
      • Latin America Circulating Tumor Cells Market, By Specimen
        • Blood
        • Bone marrow
        • Other body fluids
      • Latin America Circulating Tumor Cells Market, By End Use
        • Research and academic institutes
        • Hospital and clinics
        • Diagnostic centers
      • Brazil
        • Brazil Circulating Tumor Cells Market, By Technology
          • CTC detection & enrichment methods
            • Immunocapture (label-based)
              • Positive selection
              • Negative selection
            • Size-based separation (label-free)
              • Membrane-based
              • Microfluidic-based
            • Density-based separation (label-free)
            • Combined methods
          • CTC direct detection methods
            • SERS
            • Microscopy
            • Others
          • CTC analysis
        • Brazil Circulating Tumor Cells Market, By Application
          • Clinical/ liquid biopsy
            • Risk assessment
            • Screening and monitoring
          • Research
            • Cancer stem cell & tumorogenesis research
            • Drug/therapy development
        • Brazil Circulating Tumor Cells Market, By Product
          • Kits & reagents
          • Blood collection tubes
          • Devices or systems
        • Brazil Circulating Tumor Cells Market, By Specimen
          • Blood
          • Bone marrow
          • Other body fluids
        • Brazil Circulating Tumor Cells Market, By End Use
          • Research and academic institutes
          • Hospital and clinics
          • Diagnostic centers
      • Argentina
        • Argentina Circulating Tumor Cells Market, By Technology
          • CTC detection & enrichment methods
            • Immunocapture (label-based)
              • Positive selection
              • Negative selection
            • Size-based separation (label-free)
              • Membrane-based
              • Microfluidic-based
            • Density-based separation (label-free)
            • Combined methods
          • CTC direct detection methods
            • SERS
            • Microscopy
            • Others
          • CTC analysis
        • Argentina Circulating Tumor Cells Market, By Application
          • Clinical/ liquid biopsy
            • Risk assessment
            • Screening and monitoring
          • Research
            • Cancer stem cell & tumorogenesis research
            • Drug/therapy development
        • Argentina Circulating Tumor Cells Market, By Product
          • Kits & reagents
          • Blood collection tubes
          • Devices or systems
        • Argentina Circulating Tumor Cells Market, By Specimen
          • Blood
          • Bone marrow
          • Other body fluids
        • Argentina Circulating Tumor Cells Market, By End Use
          • Research and academic institutes
          • Hospital and clinics
          • Diagnostic centers
    • Middle East & Africa
      • Middle East & Africa Circulating Tumor Cells Market, By Technology
        • CTC detection & enrichment methods
          • Immunocapture (label-based)
            • Positive selection
            • Negative selection
          • Size-based separation (label-free)
            • Membrane-based
            • Microfluidic-based
          • Density-based separation (label-free)
          • Combined methods
        • CTC direct detection methods
          • SERS
          • Microscopy
          • Other
        • CTC analysis
      • Middle East & Africa Circulating Tumor Cells Market, By Application
        • Clinical/ liquid biopsy
          • Risk assessment
          • Screening and monitoring
        • Research
          • Cancer stem cell & tumorogenesis research
          • Drug/therapy development
      • Middle East & Africa Circulating Tumor Cells Market, By Product
        • Kits & reagents
        • Blood collection tubes
        • Devices or systems
      • Middle East & Africa Circulating Tumor Cells Market, By Specimen
        • Blood
        • Bone marrow
        • Other body fluids
      • Middle East & Africa Circulating Tumor Cells Market, By End Use
        • Research and academic institutes
        • Hospital and clinics
        • Diagnostic centers
      • South Africa
        • South Africa Circulating Tumor Cells Market, By Technology
          • CTC detection & enrichment methods
            • Immunocapture (label-based)
              • Positive selection
              • Negative selection
            • Size-based separation (label-free)
              • Membrane-based
              • Microfluidic-based
            • Density-based separation (label-free)
            • Combined methods
          • CTC direct detection methods
            • SERS
            • Microscopy
            • Others
          • CTC analysis
        • South Africa Circulating Tumor Cells Market, By Application
          • Clinical/ liquid biopsy
            • Risk assessment
            • Screening and monitoring
          • Research
            • Cancer stem cell & tumorogenesis research
            • Drug/therapy development
        • South Africa Circulating Tumor Cells Market, By Product
          • Kits & reagents
          • Blood collection tubes
          • Devices or systems
        • South Africa Circulating Tumor Cells Market, By Specimen
          • Blood
          • Bone marrow
          • Other body fluids
        • South Africa Circulating Tumor Cells Market, By End Use
          • Research and academic institutes
          • Hospital and clinics
          • Diagnostic centers
      • UAE
        • UAE Circulating Tumor Cells Market, By Technology
          • CTC detection & enrichment methods
            • Immunocapture (label-based)
              • Positive selection
              • Negative selection
            • Size-based separation (label-free)
              • Membrane-based
              • Microfluidic-based
            • Density-based separation (label-free)
            • Combined methods
          • CTC direct detection methods
            • SERS
            • Microscopy
            • Others
          • CTC analysis
        • UAE Circulating Tumor Cells Market, By Application
          • Clinical/ liquid biopsy
            • Risk assessment
            • Screening and monitoring
          • Research
            • Cancer stem cell & tumorogenesis research
            • Drug/therapy development
        • UAE Circulating Tumor Cells Market, By Product
          • Kits & reagents
          • Blood collection tubes
          • Devices or systems
        • UAE Circulating Tumor Cells Market, By Specimen
          • Blood
          • Bone marrow
          • Other body fluids
        • UAE Circulating Tumor Cells Market, By End Use
          • Research and academic institutes
          • Hospital and clinics
          • Diagnostic centers
      • Saudi Arabia
        • Saudi Arabia Circulating Tumor Cells Market, By Technology
          • CTC detection & enrichment methods
            • Immunocapture (label-based)
              • Positive selection
              • Negative selection
            • Size-based separation (label-free)
              • Membrane-based
              • Microfluidic-based
            • Density-based separation (label-free)
            • Combined methods
          • CTC direct detection methods
            • SERS
            • Microscopy
            • Others
          • CTC analysis
        • Saudi Arabia Circulating Tumor Cells Market, By Application
          • Clinical/ liquid biopsy
            • Risk assessment
            • Screening and monitoring
          • Research
            • Cancer stem cell & tumorogenesis research
            • Drug/therapy development
        • Saudi Arabia Circulating Tumor Cells Market, By Product
          • Kits & reagents
          • Blood collection tubes
          • Devices or systems
        • Saudi Arabia Circulating Tumor Cells Market, By Specimen
          • Blood
          • Bone marrow
          • Other body fluids
        • Saudi Arabia Circulating Tumor Cells Market, By End Use
          • Research and academic institutes
          • Hospital and clinics
          • Diagnostic centers
      • Kuwait
        • Kuwait Circulating Tumor Cells Market, By Technology
          • CTC detection & enrichment methods
            • Immunocapture (label-based)
              • Positive selection
              • Negative selection
            • Size-based separation (label-free)
              • Membrane-based
              • Microfluidic-based
            • Density-based separation (label-free)
            • Combined methods
          • CTC direct detection methods
            • SERS
            • Microscopy
            • Others
          • CTC analysis
        • Kuwait Circulating Tumor Cells Market, By Application
          • Clinical/ liquid biopsy
            • Risk assessment
            • Screening and monitoring
          • Research
            • Cancer stem cell & tumorogenesis research
            • Drug/therapy development
        • Kuwait Circulating Tumor Cells Market, By Product
          • Kits & reagents
          • Blood collection tubes
          • Devices or systems
        • Kuwait Circulating Tumor Cells Market, By Specimen
          • Blood
          • Bone marrow
          • Other body fluids
        • Kuwait Circulating Tumor Cells Market, By End Use
          • Research and academic institutes
          • Hospital and clinics
          • Diagnostic centers

Report content

Qualitative Analysis

  • Industry overview
  • Industry trends
  • Market drivers and restraints
  • Market size
  • Growth prospects
  • Porter’s analysis
  • PESTEL analysis
  • Key market opportunities prioritized
  • Competitive landscape
    • Company overview
    • Financial performance
    • Product benchmarking
    • Latest strategic developments

Quantitative Analysis

  • Market size, estimates, and forecast from 2018 to 2030
  • Market estimates and forecast for product segments up to 2030
  • Regional market size and forecast for product segments up to 2030
  • Market estimates and forecast for application segments up to 2030
  • Regional market size and forecast for application segments up to 2030
  • Company financial performance
What questions do you have? Get quick response from our industry experts. Request a Free Consultation

Research Methodology

Grand View Research employs a comprehensive and iterative research methodology focused on minimizing deviance in order to provide the most accurate estimates and forecast possible. The company utilizes a combination of bottom-up and top-down approaches for segmenting and estimating quantitative aspects of the market. In Addition, a recurring theme prevalent across all our research reports is data triangulation that looks market from three different perspectives. Critical elements of the methodology employed for all our studies include:

Preliminary data mining

Raw market data is obtained and collated on a broad front. Data is continuously filtered to ensure that only validated and authenticated sources are considered. In addition, data is also mined from a host of reports in our repository, as well as a number of reputed paid databases. For a comprehensive understanding of the market, it is essential to understand the complete value chain, and in order to facilitate this; we collect data from raw material suppliers, distributors as well as buyers.

Technical issues and trends are obtained from surveys, technical symposia, and trade journals. Technical data is also gathered from an intellectual property perspective, focusing on white space and freedom of movement. Industry dynamics with respect to drivers, restraints, pricing trends are also gathered. As a result, the material developed contains a wide range of original data that is then further cross-validated and authenticated with published sources.

Statistical model

Our market estimates and forecasts are derived through simulation models. A unique model is created customized for each study. Gathered information for market dynamics, technology landscape, application development, and pricing trends are fed into the model and analyzed simultaneously. These factors are studied on a comparative basis, and their impact over the forecast period is quantified with the help of correlation, regression, and time series analysis. Market forecasting is performed via a combination of economic tools, technological analysis, industry experience, and domain expertise.

Econometric models are generally used for short-term forecasting, while technological market models are used for long-term forecasting. These are based on an amalgamation of the technology landscape, regulatory frameworks, economic outlook, and business principles. A bottom-up approach to market estimation is preferred, with key regional markets analyzed as separate entities and integration of data to obtain global estimates. This is critical for a deep understanding of the industry as well as ensuring minimal errors. Some of the parameters considered for forecasting include:

    • Market drivers and restraints, along with their current and expected impact
    • Raw material scenario and supply v/s price trends
    • Regulatory scenario and expected developments
    • Current capacity and expected capacity additions up to 2030

We assign weights to these parameters and quantify their market impact using weighted average analysis, to derive an expected market growth rate.

Primary validation

This is the final step in estimating and forecasting for our reports. Exhaustive primary interviews are conducted, face to face as well as over the phone to validate our findings and assumptions used to obtain them. Interviewees are approached from leading companies across the value chain including suppliers, technology providers, domain experts, and buyers so as to ensure a holistic and unbiased picture of the market. These interviews are conducted across the globe, with language barriers overcome with the aid of local staff and interpreters. Primary interviews not only help in data validation but also provide critical insights into the market, current business scenario, and future expectations and enhance the quality of our reports. All our estimates and forecast are verified through exhaustive primary research with Key Industry Participants (KIPs) which typically include:

    • Market-leading companies
    • Raw material suppliers
    • Product distributors
    • Buyers

The key objectives of primary research are as follows:

    • To validate our data in terms of accuracy and acceptability
    • To gain an insight in to the current market and future expectations

Data Collection Matrix

Perspective

Primary research

Secondary research

Supply-side
  • Manufacturers
  • Technology distributors and wholesalers
  • Company reports and publications
  • Government publications
  • Independent investigations
  • Economic and demographic data

Demand-side
  • End-user surveys
  • Consumer surveys
  • Mystery shopping
  • Case studies
  • Reference customers


Industry Analysis Matrix

Qualitative analysis

Quantitative analysis
  • Industry landscape and trends
  • Market dynamics and key issues
  • Technology landscape
  • Market opportunities
  • Porter’s analysis and PESTEL analysis
  • Competitive landscape and component benchmarking
  • Policy and regulatory scenario
  • Market revenue estimates and forecast up to 2030
  • Market revenue estimates and forecasts up to 2030, by technology
  • Market revenue estimates and forecasts up to 2030, by application
  • Market revenue estimates and forecasts up to 2030, by type
  • Market revenue estimates and forecasts up to 2030, by component
  • Regional market revenue forecasts, by technology
  • Regional market revenue forecasts, by application
  • Regional market revenue forecasts, by type
  • Regional market revenue forecasts, by component

 

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
Jump to content
pdf icn

GET A FREE SAMPLE

arrow icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

Or view our licence options:

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.